Table 2.
Clinical characteristics of patients with inflammatory bowel disease.
| VEO-IBD | Pediatric IBD | P-value | |
|---|---|---|---|
| n | 66 | 46 | |
| Type of IBD, n (%) | 0.010 | ||
| Crohn’s Disease | 39 (59.1) | 38 (82.6) | |
| IBD-unclassified | 24 (36.4) | 5 (10.9) | |
| Ulcerative Colitis | 3 (4.5) | 3 (6.5) | |
| Paris Classification of Pediatric IBD | |||
| Crohn disease: Lower GI Disease location, n (%) | 0.001 | ||
| Ileal (L1) | 3 (8) | 9 (24) | |
| Colonic (L2) | 24 (62) | 9 (24) | |
| Ileocolonic (L3) | 11 (28) | 18 (47) | |
| None | 1 (2.5) | 2 (5) | |
| Crohn disease: Upper GI Disease location, n (%) | <0.001 | ||
| L4a | 8 (21) | 17 (44) | |
| L4b | 0 | 3 (8) | |
| L4a/L4b | 3 (8) | 4 (11) | |
| None | 28 (72) | 14 (37) | |
| Crohn disease behavior, n (%) | 0.014 | ||
| Inflammatory (B1) | 37 (95) | 31 (82) | |
| Stricturing (B2) | 1 (1.5) | 5 (13) | |
| Stricturing and Penetrating (B2/B3) | 1 (3.0) | 2 (5) | |
| Ulcerative colitis/IBD-U extent, n (%) | 0.027 | ||
| Left-sided colitis (E2) | 2 (7) | 3 (38) | |
| Extensive colitis (E3) | 4 (15) | 0 (0) | |
| Pancolitis (E4) | 20 (74) | 5 (62) | |
| None | 1(4) | 0 (0) | |
| IBD Treatments | |||
| Newly diagnosed, n (%) | 23 (34.8) | 27 (58.7) | 0.021 |
| Therapies newly initiated during the study, n (%) | |||
| Aminosalicylates | 9 (13.6) | 13 (28.3) | 0.094 |
| Steroids | 5 (7.6) | 16 (34.8) | 0.004 |
| Immunomodulators | 5 (7.6) | 2 (4.3) | 0.766 |
| Biologic | 6 (9.1) | 15 (32.6) | 0.004 |
| Exclusive enteral nutrition therapy | 1 (1.5) | 0 (0) | 1 |
| Maintenance Therapies, n (%) | |||
| Aminosalicylates | 31 (47) | 4 (8.7) | <0.001 |
| Steroids | 12 (18.2) | 0 (0) | 0.006 |
| Immunomodulators | 14 (21.2) | 6 (13.0) | 0.390 |
| Biologic | 11 (16.7) | 17 (37.0) | 0.027 |
| Exclusive enteral nutrition therapy | 10 (15.2) | 0 (0.0) | 0.015 |
| Other Medications and Supplements, n (%) | |||
| Proton Pump Inhibitor | 6 (9.1) | 1 (2.2) | |
| Probiotics | 6 (9.1) | 4 (8.7) | |
| Iron supplements | 4 (6.1) | 2 (4.3) | |
| Fecal calprotectin, ug/g (mean (SD)) | |||
| Baseline visit | 623.54(668.42) | 1152.33 (1057.68) | 0.004 |
| Visit 2 | 688.45(783.42) | 677.10 (769.88) | 0.945 |
| Visit 3 | 568.68 (631.33) | 569.96 (825.91) | 0.994 |